0001415889-24-016570.txt : 20240612
0001415889-24-016570.hdr.sgml : 20240612
20240612200008
ACCESSION NUMBER: 0001415889-24-016570
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240611
FILED AS OF DATE: 20240612
DATE AS OF CHANGE: 20240612
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KOVEN ANDREW I
CENTRAL INDEX KEY: 0001258673
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38150
FILM NUMBER: 241039760
MAIL ADDRESS:
STREET 1: 3 COLUMBUS CIRCLE, SUITE 1710
STREET 2: C/O ARALEZ PHARMACEUTICALS INC.
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KALA BIO, Inc.
CENTRAL INDEX KEY: 0001479419
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270604595
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
BUSINESS PHONE: 781-996-5252
MAIL ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
FORMER COMPANY:
FORMER CONFORMED NAME: Kala Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20091223
4
1
form4-06122024_080605.xml
X0508
4
2024-06-11
0001479419
KALA BIO, Inc.
KALA
0001258673
KOVEN ANDREW I
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
true
false
false
false
0
Common Stock
2024-06-11
4
A
0
1750
0
A
13922
D
Stock Option (right to buy)
6.18
2024-06-11
4
A
0
3900
0
A
2034-06-10
Common Stock
3900
3900
D
Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.
Includes 10,864 unvested RSUs.
This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.
/s/ Mary Reumuth, Attorney-in-Fact
2024-06-12